Cor.At® cardiomyocytes are well - characterized mouse cardiac myocytes developed for academic and industrial cardiovascular research purposes. A more affordable alternative to human cells, but with the same high quality, Cor.At cardiomyocytes are 100% pure primary-like cardiomyocytes derived from mouse embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS cells). Cor.At cardiomyocytes replicate an in vivo cellular environment in the dish, including electrophysiology and protein expression, and are therefore perfectly suited to various applications and experimental set - ups within the pharma industry or academic research.
All common manual patch clamp set - ups as well as automated patch clamp systems (PatchXpress, Patchliner, QPatch) are supported to produce highly valuable and relevant data. Cor.At cardiomyocytes are also suitable for preclinical assessment of cardiac cytotoxicity and mitochondrial toxicity, and are a predictive model for drug profiling and target discovery (e.g. hypertrophy studies, GPCR effects, siRNA, tissue engineering). Cor.At iPSC- and ES - derived cardiomyoctes are also compatible with all common assay systems and instrumentation, including label-free detection systems.
Advantages of Cor.At human iPSC - and ESC – derived cardiomyocytes:
- 100% pure primary-like, fully characterized cardiomyocytes of mouse origin
- Ready-to-use (just thaw and plate)
- Available in different formats
Cor.At cardiomyocytes have been validated in the following applications:
- Manual and automated patch clamp
- Impedance assays
- Microelectrode array (MEA)
- Calcium transients analysis
- Cell metabolism analysis
- High content analysis (e.g., hypertrophy disease modeling)